Big Food Giants Struggle Amid Shifting Consumer Habits and Investor Doubt

Major traditional food companies, including General Mills (GIS) and Kraft Heinz (KHC), are navigating a challenging period marked by persistent inflationary pressures, evolving consumer preferences, and the increasing adoption of GLP-1 class weight-loss medications. Consumers, influenced by both rising costs and a heightened focus on health, are increasingly moving away from packaged foods, negatively impacting these companies' profitability and growth prospects. This shift has, in turn, led to a decline in investor confidence in the sector.

In an attempt to revitalize dwindling consumer demand, global food companies have recently explored various strategies. Efforts such as price reductions, increased marketing campaigns, and the addition of protein to products have, however, failed to deliver the anticipated results. General Mills' recent quarterly report, despite exceeding earnings per share expectations, revealed a significant $1.75 billion goodwill impairment charge, underscoring the structural issues confronting the company. Similarly, Kraft Heinz's total return over the past 12 months has significantly lagged the S&P 500 index. It was even noted that Kraft Heinz considered an internal company split in late 2025, driven by the adoption of GLP-1 drugs and consumers' move away from processed foods.

GLP-1 agonist medications facilitate weight loss by suppressing appetite and reducing cravings for calorie-dense, processed foods. More than 10% of American adults are now taking these drugs, and this number continues to climb. Estimates from Morgan Stanley and Barclays suggest that the widespread adoption of GLP-1 drugs could lead to a 3% to 5% reduction in the U.S. population's total calorie consumption by 2030. A more comprehensive analysis by J.P. Morgan projects an annual revenue reduction of $30-55 billion for the food and beverage industry between 2030 and 2034, with consumers potentially consuming 21% fewer calories and spending 31% less on groceries. This trend is diminishing demand for snacks, sweets, sugary beverages, and other processed foods, while simultaneously boosting interest in protein-rich, fiber-rich, and fresh produce.

These developments are directly reflected in the stock performance of food sector companies. Shares of major food companies are currently trading at their widest discount to the broader market in at least two decades. General Mills' stock has seen a decline of over 24% in the past year, while Kraft Heinz's five-year return remains negative, down over 14%. Market analysts are questioning the sustainability of these companies' high dividend yields. Indicators like the Consumer Staples Sector SPDR ETF (XLP) also reflect these ongoing pressures.

In the broader economic context, ongoing geopolitical tensions, particularly the conflict in Iran, are exacerbating the food industry's challenges by increasing shipping and raw material costs. Furthermore, retailers' pivot towards private label products and consumers' preference for more affordable alternatives pose a significant threat to national brands' market share. Rising labor costs also represent another critical factor compressing companies' profit margins.

Analysts and industry representatives anticipate that the impact of GLP-1 drugs will be lasting, fundamentally reshaping the food sector in the long term. In response to this trend, many large food companies are actively restructuring their product portfolios, introducing smaller portions and new offerings rich in protein and fiber. The upcoming introduction of oral GLP-1 medications is expected to further accelerate user adoption and intensify these market shifts. The industry's ability to swiftly and effectively respond to evolving consumer dietary habits and health-oriented demands will be a key determinant of its future success.